問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation (在職)

更新時間：2023-09-19

趙祖怡Chao, Tsu-Yi
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

38Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙祖怡

List

113Cases

2012-11-01 - 2014-12-31

Phase III

A multicentre, randomised, phase III study of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and a taxane

  • Condition/Disease

    advanced breast cancer

  • Test Drug

    JAVLOR

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2009-08-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-03-01 - 2021-02-28

Phase I

An Openlabel, Pilot Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of a Single Dose of Oradoxel in Metastatic Prostate Cancer Patients Treated With Intravenou s Docetaxel

  • Condition/Disease

    Metastatic Prostate Cancer

  • Test Drug

    Oradoxel (Docetaxel + HM30181)

Participate Sites
3Sites

Recruiting3Sites

1 8 9 10 11 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB